Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...
Shares of Corcept Therapeutics Incorporated CORT have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym (mifepristone), which is...
Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $20 Call had some of the highest...
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers